Business Overview
elbion NV is a Belgian company focused on the discovery and development of new drugs for CNS and immunological diseases. The Company has its headquarters in Leuven and also has significant R&D facilities in Radebeul, Germany.
elbion has a maturing pipeline with products in the clinic for areas of significant commercial potential and a further portfolio of high quality late pre-clinical development compounds. Naltrexone Depot is a novel, sustained release formulation of naltrexone in development for the treatment of alcohol abuse. ELB353, a highly potent PDE4 inhibitor is in Phase I trials for chronic inflammation.
elbion’s strategy is to grow its pipeline through its own integrated drug discovery activities leveraging its expertise in CNS and immunology and also by targeted in-licensing and M&A. elbion will maximise the value of its product portfolio by further partnering of its compounds and through selectively marketing products building its own sales and marketing operation.
In addition to its own clinical pipeline, elbion has a research agreement with Gilead Sciences for the discovery and development of new drugs for the treatment of hepatitis C virus (HCV) and with Wyeth Pharmaceuticals for the development of new chemical entities for the indication schizophrenia.
elbion was formed in 2006 through the merger of elbion AG and 4AZA Bioscience NV. elbion AG began operations through a management buyout from Degussa Group in 2002. 4AZA was founded in 2002 as a spin-off from the Catholic University of Leuven.
elbion´s investors include 3i, AGF Private Equity, BayTech Venture Capital, Burrill & Company, Capricorn Venture Fund, DVC Deutsche Venture Capital, Gemma Frisius Fund KU Leuven, Fortis Private Equity, GlaxoSmithKline, KBC Private Equity, Marubeni, Mitsubishi Corporation, Quintiles PharmaBio Development, Temasek Holdings and TVM Capital.
